Notice of Extraordinary General Meeting
Copenhagen, Denmark, 18 May 2021 – Notice is hereby given of an extraordinary general meeting of Curasight A/S to be held on:
Tuesday, 1 June 2021 at 11:00 am CET
Due to the COVID-19 situation, the extraordinary general meeting will be held as a completely electronic meeting without physical attendance. This is in accordance with Executive Order no. 2240 of 29 December 2020, which allows companies to conduct fully electronic general meetings even though this has not been approved in advance by the shareholders and stated in Curasight A/S’ Articles of Association. More information on how to participate in the extraordinary general meeting can be found below in the section named “practical information”.
To the shareholders of Curasight A/S
The board of directors hereby convenes an extraordinary general meeting of Curasight A/S to be held on:
Tuesday 1 June 2021 at 11:00 (CET) at Curasight A/S’ premises, Ole Maaløes Vej 3, room M4, DK-2200 Copenhagen N, Denmark.
The agenda for the general meeting is as follows:
- ELECTION OF DR. KIRSTEN DREJER AS NEW MEMBER OF THE BOARD OF DIRECTORS
- MISCELLANEOUS
Complete agenda:
Re 1: Election of Dr. Kirsten Drejer as new member of the board of directors
The board of directors proposes Dr. Kirsten Drejer as new member of the board of directors. A list of Dr. Kirsten Drejer’s management positions in other companies is enclosed as appendix 1.
Practical information
Special circumstances due to COVID-19
Extraordinary general meeting (without the possibility of physical attendance)
As mentioned above the extraordinary general meeting will be held without the possibility of physical attendance at the meeting due to the Covid-19 situation.
Curasight A/S will comply with the recommendations coming from the authorities due to COVID-19. The shareholders are encouraged to participate at the general meeting using Microsoft Teams or utilize the possibility to submit a proxy to the board of directors or vote by correspondence.
Microsoft Teams
In order to join the general meeting using Microsoft Teams please write an email to uk@curasight.com whereupon you will receive instructions of how to participate using Microsoft Teams. If possible, such e-mail shall be received no later than 25 May 2021 at 4:00 pm CET.
Proxy
The shareholders may vote by proxy at the general meeting. A proxy form can be found on the company’s website (www.curasight.com). Voting instructions by proxy shall be submitted by returning the proxy form, duly completed and signed, by email to uk@curasight.com. If possible, proxies shall be submitted no later than 25 May 2021 at 4:00 pm CET.
Voting by Correspondence
Shareholders may – instead of voting in person at the general meeting – choose to vote by correspondence, i.e. voting in writing prior to the general meeting. A voting by correspondence form can be found on the company’s website (www.curasight.com). Any shareholder who wishes to vote by correspondence shall submit the voting by correspondence form, duly completed and signed, by email to uk@curasight.com. Votes delivered by correspondence must, if possible, be submitted no later than 25 May 2021 at 4:00 pm CET and cannot be revoked.
Information:
To adopt the proposal under item 1, a simple majority of the votes cast is required.
Appendix 1
Dr. Kirsten Drejers current board directorships and management positions
2017 - Bioneer (www.bioneer.dk), Chairman of the board
2017 - Lyhne & Co (www.lyhne.dk), Board member
2017 - Antag (www.antag.com), Chairman of the board
2017 - Resother Pharma (www.resotherpharma.com), Chairman of the board
2018 - Zealand Pharma (www.zealandpharma.com), Board member
For more information regarding Curasight A/S, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.